Table 1. Association of CYP1B1 expression with the clinicopathologic characteristics of RCC.
| Pathologicalvariables | Total (n = 59),n (%) | CYP1B1 expression | P | ||
|---|---|---|---|---|---|
| Weak (n = 17) | Moderate (n = 19) | Strong (n = 23) | |||
| Age | |||||
| Mean ± SD, years | 66.2 ± 6.8 | - | - | - | |
| Sex | |||||
| Men | 37/59 (62.7) | 12/37 (45.9) | 10/37 (27.0) | 15/37 (40.5) | 0.5201 |
| Women | 22/59 (37.2) | 5/22 (22.7) | 9/22 (40.9) | 8/22 (36.4) | |
| Histological type | |||||
| Clear cell | 49/59 (83.0) | 13/49 (26.5) | 17/49 (34.7) | 19/49 (38.8) | 0.5204 |
| Papillary | 7/59 (11.9) | 2/7 (28.6) | 1/7 (14.3) | 4/7 (57.1) | |
| Granular | 1/59 (1.7) | - | 1/1 (100) | - | |
| Tubular | 1/59 (1.7) | 1/1 (100) | - | - | |
| Oncocytoma | 1/59 (1.7) | 1/1 (100) | - | - | |
| Tumor stage | |||||
| pT1 | 31/59 (52.5) | 9/31 (29.0) | 7/31 (22.6) | 11/31 (35.5) | 0.0977 |
| pT2 | 11/59 (18.6) | 2/11 (18.2) | 4/31 (12.9) | 9 (81.8) | |
| pT3 | 13/59 (22.0) | 6/13 (46.2) | 6/13 (46.2) | 1/13 (7.7) | |
| pT4 | 4/59 (6.8) | - | 2/4 (50.0) | 2/4 (50.0) | |
| Nuclear grade | |||||
| 1 | 35/59 (59.3) | 14/35 (40.0) | 12/35 (34.3) | 9/35 (25.7) | 0.1656 |
| 2 | 14/59 (23.7) | 2/14 (14.3) | 3/14 (21.4) | 9/14 (64.2) | |
| 3 | 6/59 (10.2) | 1/6 (16.7) | 2/6 (33.3) | 3/6 (50.0) | |
| 4 | 4/59 (8.5) | - | 2/4 (50.0) | 2/4 (50.0) | |
| Vascular invasion | |||||
| Negative | 56/59 (94.9) | - | - | - | |
| Positive | 3/59 (5.1) | - | - | - | |
| Capsular invasion | |||||
| Negative | 57/59 (96.6) | - | - | - | |
| Positive | 2/59 (3.4) | - | - | - | |